All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group

MorphoSys seizes FOMC glee to get €84m and zero discount

German biotechnology firm MorphoSys raised €84m through a sale of new shares on Wednesday night. Pre-sounding gave bankers the confidence to launch the deal before any statements from Wednesday's Federal Open Market Committee meetings in the US, but the positive market reaction to the news later that the Fed was not looking to reduce its bond-buying programme immediately helped the deal to price with no discount.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree